Skip to content
Clinical Trials – home

Hospital Universitario Puerta Del Mar

Research site

Spain Avenida De Ana De Viya 21, 11009 Cadiz, Spain

  • 25 trials recruiting
  • Hidradenitis · Bladder transitional cell carcinoma · Asthma
  • Adults and children

About Specializations

Hospital Universitario Puerta Del Mar in Cadiz, Spain specialises in clinical trials of conditions such as Hidradenitis, Bladder transitional cell carcinoma, Asthma, Multiple sclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Hematology and Cancer Research

At Hospital Universitario Puerta Del Mar, clinical trials in neoplasms focus on cancers such as acute myeloid leukemia, lymphoma, breast cancer, bladder cancer, prostate cancer, and pancreatic cancer. These studies are mainly designed to test new treatment strategies, compare them with current care, and improve outcomes for patients with difficult-to-treat malignancies.

  • Testing new approaches for blood cancers, including acute myeloid leukemia and B-cell lymphoma
  • Evaluating treatment options in breast cancer, prostate cancer, and pancreatic adenocarcinoma
  • Studying bladder cancer care in non-muscle-invasive and muscle-invasive disease

The site’s work in oncology also includes efforts to improve survival, delay progression, and refine treatment choices for patients with advanced or high-risk disease.

Cardiovascular and Metabolic Medicine

Research in cardiovascular diseases and nutritional and metabolic diseases includes studies in severe hypertriglyceridemia, aortic stenosis, spontaneous coronary artery dissection, cardiomyopathy, and familial hypercholesterolemia. These trials aim to improve prevention, reduce complications, and assess whether newer therapies can better control risk factors and cardiovascular events.

  • Exploring treatments for severe hypertriglyceridemia and heterozygous familial hypercholesterolemia
  • Assessing care for spontaneous coronary artery dissection and severe symptomatic aortic stenosis
  • Studying therapies for idiopathic dilated cardiomyopathy and secondary prevention of cardiovascular events

This area reflects a strong interest in both long-term risk reduction and better management of serious heart and lipid disorders.

Neurology and Multiple Sclerosis

Trials in nervous system diseases at this site address multiple sclerosis, relapsing multiple sclerosis, primary progressive multiple sclerosis, migraine, medication overuse headache, and cervical dystonia. The main goal is to evaluate treatments that may reduce relapses, improve disability outcomes, and ease symptoms that affect daily life.

  • Testing therapies for relapsing and primary progressive multiple sclerosis
  • Studying options for migraine and medication overuse headache
  • Evaluating symptom relief in cervical dystonia and fatigue-related neurologic conditions

The Hospital Universitario Puerta Del Mar contributes to research aimed at improving both disease control and quality of life in chronic neurologic disorders.

Respiratory, Kidney, and Critical Care Research

Studies in respiratory tract diseases and immune-related complications include idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, eosinophilic asthma, septic shock, acute pancreatitis, and kidney-related problems such as delayed graft function after kidney transplantation. These trials are focused on finding better ways to preserve organ function, reduce severe complications, and support recovery in high-risk patients.

  • Evaluating treatments for pulmonary fibrosis and severe asthma
  • Investigating care for septic shock and acute pancreatitis
  • Studying kidney transplant outcomes, including delayed graft function and infection prevention

This research combines intensive-care, lung, and transplant medicine with the aim of improving survival and recovery in complex clinical settings.

Inflammatory, Skin, and Immune-Mediated Diseases

A substantial part of the portfolio covers immune system diseases, skin and connective tissue diseases, and related inflammatory conditions such as hidradenitis suppurativa, chronic spontaneous urticaria, and atopic dermatitis. These trials are designed to assess whether new therapies can better control inflammation, reduce symptoms, and maintain long-term disease improvement.

  • Testing treatment options for hidradenitis suppurativa and chronic spontaneous urticaria
  • Evaluating therapies for atopic dermatitis in children and adults
  • Measuring symptom reduction and durability of response in chronic inflammatory skin disease

The research reflects a strong focus on persistent immune-driven conditions where patients often need better long-term control.

Eye, Digestive, and Pediatric Research

Additional trials at Hospital Universitario Puerta Del Mar span eye diseases, digestive system diseases, and neonatal and pediatric care. Areas of interest include corneal disease, myopia, pancreatitis, hepatocellular carcinoma, and prematurity in neonates. The purpose of these studies is to improve treatment options, slow disease progression, and support vulnerable patient groups.

  • Studying therapies for corneal ulcers and myopia progression
  • Evaluating care in acute and recurrent pancreatitis
  • Researching support strategies for preterm neonates and liver cancer patients

This mix of studies shows a broad clinical research profile, extending from vision and digestion to early-life medicine and liver oncology.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida De Ana De Viya 2111009 CadizSpain
Recruiting now
25 trials
Conditions studied
69

More sites in CadizSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

75 clinical trials

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Torticollis

Recruiting

Study on IPN10200 for Treating Cervical Dystonia in Adults

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Study on the Safety and Absorption of Meropenem and Vaborbactam in Children with Complicated Urinary Tract Infections

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Meropenem
  • Sponsor:Menarini Ricerche S.p.A.

Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:TYRA-300-B01
  • Sponsor:Tyra Biosciences Inc.

Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Lepidoglyphus destructor Immunotherapy for Allergic Rhinitis and Rhinoconjunctivitis in Patients With or Without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Allergen extracts
  • Sponsor:Inmunotek S.L.

Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic vein tissue segment, decellularised, with a functional valve perfused with autologous peripheral blood
  • Sponsor:VeriGraft AB

Asthma

Recruiting

A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Fundacion PETHEMA

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Study of UGN-104 (mitomycin) treatment for patients with low-grade upper tract urothelial cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.